Who is more likely to lose weight on tirzepatide and why? — Mounjaro Treatment for Weight Loss in Marbella

26/10/2024

Tirzepatide is an injection that is given once a week to adults who are obese. It helps people lose weight by targeting two specific receptors in the body called GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), both of which are involved in controlling appetite and metabolism. Tirzepatide has demonstrated significant promise in clinical trials for weight loss, as evidenced by the data from the SURMOUNT clinical trials, which indicates that both men and women experienced significant reductions in body weight, though women generally lost a greater percentage of weight than men. Here, we talk about these clinical trials and our Mounjaro treatment for weight loss in Marbella, a tirzepatide treatment.

The Growing Obesity Epidemic

Approximately 650 million persons worldwide suffer from obesity, which is one of the most prevalent chronic health diseases. Obesity can cause a number of major health issues, such as:

Heart disease
Type 2 diabetes
Increased healthcare costs

To lower these risks, obesity management is essential, and drugs like tirzepatide are offering fresh, practical approaches.

Understanding How Tirzepatide Works

Traditionally, GLP-1—a hormone that aids in controlling hunger and energy balance—has been the main focus of weight loss therapies. Tirzepatide, however, takes things a step further by concentrating on GIP, another hormone that plays a role in controlling weight. It has been demonstrated that this dual-target strategy works better than treatments that just target GLP-1.

Tirzepatide was shown to aid in weight loss in mice more effectively than therapies that solely targeted GLP-1 in early study. Promising outcomes from clinical trials on type 2 diabetic patients suggest that this drug may also be very helpful in helping non-diabetics lose weight.

Key Findings from the SURMOUNT Trials

The purpose of the SURMOUNT clinical trials was to assess tirzepatide's effectiveness in helping overweight or obese adults lose weight. SURMOUNT-1 (SM-1) to SURMOUNT-4 (SM-4) were the four studies that made up these trials, with a combined total of around 4,700 participants.

These are a few of the main conclusions:

Significant Weight Loss: Tirzepatide caused significant weight losses in both men and women at all dosages.
Disparities Based on Sex: Men dropped up to 18.1% of their body weight while women lost up to 24.6%. In every study, this difference was statistically significant.
Success Rates: Compared to a placebo, tirzepatide significantly increased the likelihood for both men and women to reach weight loss milestones (5%, 10%, and 15% reductions in body weight).

Impact of Lifestyle Changes on Weight Loss

The trials also provided fascinating findings about the effect of lifestyle changes on weight loss outcomes. While some trials, such as SM-1 and SM-2, featured individuals who were randomised directly after a screening period, others had lead-in periods with lifestyle interventions:

SM-3 Trial: It included a 12-week lead-in phase focused on extensive lifestyle adjustments prior to randomisation.
SM-4 Trial: A 36-week lead-in phase was paired with open-label tirzepatide therapy.

Despite these disparities, men and women in all trials lost significant weight with tirzepatide.

Weight Loss and Safety Outcomes

In terms of safety, the tests revealed that tirzepatide was well tolerated by both men and women. Women experienced more nausea and vomiting than males, which is a common side effect of drugs in this class.

Why Women Lost More Weight

One of the most intriguing outcomes from the SURMOUNT studies was that women lost a higher percentage of their body weight than men. While the exact reason for this discrepancy is unknown, researchers believe it could be due to differences in metabolism, fat distribution, or hormonal responses between men and women.

In the SM-3 trial, for example, women were more likely than males to reach 5% and 10% weight loss milestones, implying that tirzepatide may be more effective in specific situations.

Personalized Weight Loss Treatments: A New Frontier

The findings from the SURMOUNT studies pave the way for more personalised approaches to weight reduction treatment. Given indications that women may react differently to tirzepatide than males, healthcare professionals could utilise this knowledge to adjust therapies depending on individual criteria such as gender, metabolic rate, and overall health state.

This type of personalised care could lead to more effective weight loss solutions, assisting patients in meeting their objectives and improving their long-term health results.

Mounjaro Treatment for Weight Loss in Marbella

Tirzepatide offers a significant development in the treatment of obesity. By targeting both GIP and GLP-1 receptors, it provides a novel strategy to weight management that has already demonstrated considerable advantages in clinical trials.

Some of the benefits are:

Greater Weight Loss: Patients on tirzepatide are more likely to lose weight than those receiving typical therapies.
Improved Health: Losing weight can reduce your risk of heart disease, type 2 diabetes, and other obesity-related issues.
Potential for Personalized Treatment Plans: Tirzepatide has the potential to be employed in personalised weight loss strategies suited to each individual's unique needs, pending further research.

If you're battling with obesity and looking for an efficient strategy to lose weight, tirzepatide could be the answer. At Helicopteros Sanitarios, we provide Mounjaro treatment for weight loss in Marbella. This cutting-edge technique has showed significant promise in helping people lose weight safely and successfully.

Take control of your health now. Contact us today to find out how our Mounjaro therapy might help you begin your weight loss journey. Our team is here to help you every step of the way.